As a result of a $2.085-million investment from the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), a contract manufacturing and drug development research company in Toronto’s North York district will undergo renovations and an expansion. The company, Dalton Pharma Services (Dalton), will also provide $6.3-million in funding to finance the project.

“Dalton is very pleased and grateful to have been selected by FedDev Ontario for this important funding,” says Peter Pekos, President and CEO, Dalton Chemical Laboratories Inc. “The resulting strategic investments we are making in sterile manufacturing will help Dalton advance its leadership position in aseptic processing technologies, and accelerate the application of these innovations to our customer’s leading-edge pharmaceutical products.”

The expansion and renovations, which are part of FedDev Ontario’s Investing in Business Growth and Productivity initiative, will allow Dalton to manufacture more specialized drug products, improve current development capabilities, and expand the range of services they provide to clients.

During construction, the project will support the creation of 21 new full-time life sciences positions with an additional 13 to follow.